179461-52-0 Usage
Description
PD 151746 is a cell-permeable calpain inhibitor that is known for its ability to induce pertussis toxin (PTx)-sensitive chemotaxis in neutrophils and human monocytes. It plays a significant role in the inhibition of inflammation, making it a potential candidate for various pharmaceutical applications.
Uses
Used in Pharmaceutical Industry:
PD 151746 is used as an anti-inflammatory agent for its ability to inhibit inflammation by targeting calpain, a calcium-activated cysteine protease involved in various cellular processes, including inflammation.
Used in Immunology Research:
In the field of immunology, PD 151746 is used as a research tool to study the role of calpain in immune cell function, particularly in neutrophils and human monocytes. Its ability to induce chemotaxis in these cells helps researchers understand the underlying mechanisms of immune response and inflammation.
Used in Drug Development:
PD 151746 serves as a potential lead compound in the development of new drugs targeting calpain-mediated inflammation. Its cell-permeable nature and specificity for calpain make it a valuable starting point for designing more potent and selective inhibitors for various inflammatory conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 179461-52-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,9,4,6 and 1 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 179461-52:
(8*1)+(7*7)+(6*9)+(5*4)+(4*6)+(3*1)+(2*5)+(1*2)=170
170 % 10 = 0
So 179461-52-0 is a valid CAS Registry Number.
179461-52-0Relevant articles and documents
ALPHA-MERCAPTOACRYLIC ACID DERIVATIVES HAVING CALPAIN INHIBITORY ACTIVITY
-
, (2008/06/13)
The invention covers a novel series of α-mercaptoacrylic acid derivatives that inhibit both calpain I and calpain II with a high affinity and selectivity. The compounds are useful in the treatment of neurodegenerative disorders including cerebrovascular disorders, brain injury, spinal cord, and peripheral nerve injury, cardiac infarction, cataracts, inflammation, restenosis, muscular dystrophy, and platelet aggregation. Pharmaceutical compositions, methods of using processes for preparing and novel intermediates useful in the processes are also disclosed.